ECSP14025016A - Diagnóstico farmacéutico - Google Patents
Diagnóstico farmacéuticoInfo
- Publication number
- ECSP14025016A ECSP14025016A ECIEPI201425016A ECPI201425016A ECSP14025016A EC SP14025016 A ECSP14025016 A EC SP14025016A EC IEPI201425016 A ECIEPI201425016 A EC IEPI201425016A EC PI201425016 A ECPI201425016 A EC PI201425016A EC SP14025016 A ECSP14025016 A EC SP14025016A
- Authority
- EC
- Ecuador
- Prior art keywords
- amide
- pi3k
- thiazol
- trifluoro
- pyrrolidine
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000003197 catalytic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 2,2,2-trifluoro-1,1-dimethyl-ethyl Chemical group 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se basa en el hallazgo de que la identidad del ácido nucleico que codifica un aminoácido en la posición 859 de la subunidad catalítica p110α de PI3K se puede utilizar para seleccionar a los individuos que tengan cáncer que tengan probabilidades de responder al tratamiento con una cantidad terapéuticamente efectiva de un compuesto inhibidor de PI3K específico de la isoforma alfa, tal como 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (S)-pirrolidin-1,2-dicarboxílico, o una sal farmacéuticamente aceptable de la misma. De una manera específica, se encontró que se puede utilizar una alteración del residuo de glutamina (también referida en la presente como una Q o Gln), en la posición 859 de la subunidad catalítica p110α de PI3K en una muestra a partir de un individuo que tenga cáncer, para determinar si ese individuo responderá al tratamiento con el compuesto inhibidor de PI3K específico de la isoforma alfa 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (S)-pirrolidin-1,2-dicarboxílico, o una sal farmacéuticamente aceptable de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617284P | 2012-03-29 | 2012-03-29 | |
| US201361767848P | 2013-02-22 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14025016A true ECSP14025016A (es) | 2015-09-30 |
Family
ID=48083130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201425016A ECSP14025016A (es) | 2012-03-29 | 2014-10-29 | Diagnóstico farmacéutico |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9795596B2 (es) |
| EP (1) | EP2830621B1 (es) |
| JP (1) | JP6224067B2 (es) |
| KR (1) | KR20140138771A (es) |
| CN (1) | CN104271136A (es) |
| AR (1) | AR090544A1 (es) |
| AU (1) | AU2013241752B2 (es) |
| BR (1) | BR112014023530A2 (es) |
| CA (1) | CA2866127A1 (es) |
| CL (1) | CL2014002576A1 (es) |
| CO (1) | CO7091176A2 (es) |
| EA (1) | EA028984B1 (es) |
| EC (1) | ECSP14025016A (es) |
| ES (1) | ES2845560T3 (es) |
| GT (1) | GT201400206A (es) |
| HK (1) | HK1200723A1 (es) |
| IL (1) | IL234658B (es) |
| IN (1) | IN2014DN08970A (es) |
| MX (1) | MX2014011682A (es) |
| NZ (1) | NZ628596A (es) |
| PH (1) | PH12014502168A1 (es) |
| SG (2) | SG10201608001RA (es) |
| TW (1) | TW201345525A (es) |
| WO (1) | WO2013144249A1 (es) |
| ZA (1) | ZA201405938B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015144019A (ru) * | 2013-03-15 | 2017-04-24 | Новартис Аг | Биомаркеры фармакодинамического ответа опухоли |
| WO2015172085A2 (en) | 2014-05-09 | 2015-11-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| KR102598782B1 (ko) * | 2014-10-03 | 2023-11-07 | 노파르티스 아게 | 알펠리십을 포함하는 제약 조성물 |
| RU2018123524A (ru) * | 2015-12-03 | 2020-01-09 | Новартис Аг | Фармацевтическая диагностика |
| WO2019199860A1 (en) * | 2018-04-09 | 2019-10-17 | The Research Foundation For The State University Of New York | Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| ATE92538T1 (de) | 1988-01-21 | 1993-08-15 | Genentech Inc | Verstaerkung und nachweis von nukleinsaeuresequenzen. |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| ATE138106T1 (de) | 1988-07-20 | 1996-06-15 | David Segev | Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen |
| US5169766A (en) | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| US8513221B2 (en) * | 2008-07-07 | 2013-08-20 | Xcovery Holding, LLC | PI3K isoform selective inhibitors |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
-
2013
- 2013-03-27 AU AU2013241752A patent/AU2013241752B2/en not_active Ceased
- 2013-03-27 HK HK15101259.7A patent/HK1200723A1/xx unknown
- 2013-03-27 EA EA201491787A patent/EA028984B1/ru not_active IP Right Cessation
- 2013-03-27 WO PCT/EP2013/056600 patent/WO2013144249A1/en not_active Ceased
- 2013-03-27 JP JP2015502341A patent/JP6224067B2/ja not_active Expired - Fee Related
- 2013-03-27 IN IN8970DEN2014 patent/IN2014DN08970A/en unknown
- 2013-03-27 NZ NZ628596A patent/NZ628596A/en not_active IP Right Cessation
- 2013-03-27 ES ES13715169T patent/ES2845560T3/es active Active
- 2013-03-27 KR KR1020147026735A patent/KR20140138771A/ko not_active Ceased
- 2013-03-27 EP EP13715169.2A patent/EP2830621B1/en active Active
- 2013-03-27 SG SG10201608001RA patent/SG10201608001RA/en unknown
- 2013-03-27 US US14/387,653 patent/US9795596B2/en not_active Expired - Fee Related
- 2013-03-27 CN CN201380017393.0A patent/CN104271136A/zh active Pending
- 2013-03-27 BR BR112014023530A patent/BR112014023530A2/pt not_active IP Right Cessation
- 2013-03-27 AR ARP130101029 patent/AR090544A1/es unknown
- 2013-03-27 CA CA 2866127 patent/CA2866127A1/en not_active Abandoned
- 2013-03-27 SG SG11201405169SA patent/SG11201405169SA/en unknown
- 2013-03-27 MX MX2014011682A patent/MX2014011682A/es unknown
- 2013-03-28 TW TW102111262A patent/TW201345525A/zh unknown
-
2014
- 2014-08-13 ZA ZA2014/05938A patent/ZA201405938B/en unknown
- 2014-09-15 IL IL234658A patent/IL234658B/en not_active IP Right Cessation
- 2014-09-26 CL CL2014002576A patent/CL2014002576A1/es unknown
- 2014-09-26 PH PH12014502168A patent/PH12014502168A1/en unknown
- 2014-09-29 GT GT201400206A patent/GT201400206A/es unknown
- 2014-09-29 CO CO14215143A patent/CO7091176A2/es unknown
- 2014-10-29 EC ECIEPI201425016A patent/ECSP14025016A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013241752B2 (en) | 2016-07-07 |
| SG10201608001RA (en) | 2016-11-29 |
| PH12014502168A1 (en) | 2014-12-10 |
| NZ628596A (en) | 2015-10-30 |
| EP2830621A1 (en) | 2015-02-04 |
| HK1200723A1 (en) | 2015-08-14 |
| SG11201405169SA (en) | 2014-10-30 |
| CA2866127A1 (en) | 2013-10-03 |
| KR20140138771A (ko) | 2014-12-04 |
| ZA201405938B (en) | 2015-11-25 |
| US9795596B2 (en) | 2017-10-24 |
| US20150111927A1 (en) | 2015-04-23 |
| IN2014DN08970A (es) | 2015-05-22 |
| AR090544A1 (es) | 2014-11-19 |
| JP2015514080A (ja) | 2015-05-18 |
| BR112014023530A2 (pt) | 2017-07-18 |
| AU2013241752A1 (en) | 2014-09-25 |
| MX2014011682A (es) | 2015-01-22 |
| CL2014002576A1 (es) | 2015-01-23 |
| EP2830621B1 (en) | 2020-10-21 |
| EA201491787A1 (ru) | 2015-01-30 |
| IL234658B (en) | 2018-02-28 |
| ES2845560T3 (es) | 2021-07-27 |
| EA028984B1 (ru) | 2018-01-31 |
| WO2013144249A1 (en) | 2013-10-03 |
| TW201345525A (zh) | 2013-11-16 |
| CO7091176A2 (es) | 2014-10-21 |
| GT201400206A (es) | 2017-09-28 |
| CN104271136A (zh) | 2015-01-07 |
| JP6224067B2 (ja) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| CO2020009625A2 (es) | Inhibidor de fap | |
| CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| CL2016000215A1 (es) | Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14). | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| CY1120079T1 (el) | Υδατικη συνθεση που περιεχει βρωμεξινη | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| TR201901110T4 (tr) | Empagliflozinin terapötik kullanımları. | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| MX2021014242A (es) | Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora. | |
| AR102463A1 (es) | Inhibidor de cinasa aurora a | |
| CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
| ECSP14025016A (es) | Diagnóstico farmacéutico | |
| DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| BR112015020466A2 (pt) | inibidores de cdc7 | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| BR112013032456A2 (pt) | anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer | |
| BR112015001212A2 (pt) | terapia de combinação de inibidores de igf1 r e pi3k | |
| BR112018011851A2 (pt) | compostos de isoindol | |
| BR112017004694A2 (pt) | composições farmacêuticas compreendendo alpelisibe |